GB1179787A - Stabilised and Potentiated Therapeutic Enzyme Compositions - Google Patents

Stabilised and Potentiated Therapeutic Enzyme Compositions

Info

Publication number
GB1179787A
GB1179787A GB04095/67A GB1409567A GB1179787A GB 1179787 A GB1179787 A GB 1179787A GB 04095/67 A GB04095/67 A GB 04095/67A GB 1409567 A GB1409567 A GB 1409567A GB 1179787 A GB1179787 A GB 1179787A
Authority
GB
United Kingdom
Prior art keywords
march
therapeutic enzyme
stabilised
enzyme compositions
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB04095/67A
Inventor
Frantisek Popper
Siegfried Gottfried
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biorex Laboratories Ltd
Original Assignee
Biorex Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biorex Laboratories Ltd filed Critical Biorex Laboratories Ltd
Priority to GB04095/67A priority Critical patent/GB1179787A/en
Priority to FR144695A priority patent/FR8032M/fr
Priority to DE19681767038 priority patent/DE1767038A1/en
Publication of GB1179787A publication Critical patent/GB1179787A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/486—Elastase (3.4.21.36 or 3.4.21.37)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1,179,787. Therapeutic enzyme preparations. BIOREX LABORATORIES Ltd. 14 March, 1968 [22 March, 1967; 28 March, 1967], Nos. 13394/67 and 14095/67. Heading A5B. [Also in Division C3] Compositions for treating allergic conditions comprise hyaluronidose and/or glucuronylcosaminoglycan hyaluronate lyase and at least one compound selected from #-glucuronidase, #-N-acetylhexasaminidase, trypsin, chymotrypsin, elastase, ficin, pepsin, streptokinase and lysozyme. They may also contain poly-L-lysine, albumin or protamine and a carrier to render the composition suitable for administration by injection, scarification, ingestion, inhalation or dermally.
GB04095/67A 1967-03-22 1967-03-22 Stabilised and Potentiated Therapeutic Enzyme Compositions Expired GB1179787A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GB04095/67A GB1179787A (en) 1967-03-22 1967-03-22 Stabilised and Potentiated Therapeutic Enzyme Compositions
FR144695A FR8032M (en) 1967-03-22 1968-03-21
DE19681767038 DE1767038A1 (en) 1967-03-22 1968-03-22 drug

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB04095/67A GB1179787A (en) 1967-03-22 1967-03-22 Stabilised and Potentiated Therapeutic Enzyme Compositions
GB1339467 1967-03-22

Publications (1)

Publication Number Publication Date
GB1179787A true GB1179787A (en) 1970-01-28

Family

ID=26249753

Family Applications (1)

Application Number Title Priority Date Filing Date
GB04095/67A Expired GB1179787A (en) 1967-03-22 1967-03-22 Stabilised and Potentiated Therapeutic Enzyme Compositions

Country Status (3)

Country Link
DE (1) DE1767038A1 (en)
FR (1) FR8032M (en)
GB (1) GB1179787A (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0106812A2 (en) * 1982-10-08 1984-04-25 Istituto Farmacologico Serono Pharmaceutical composition containing a fibrinolytic agent and a diffusion factor, useful for the treatment of the myocardium infarction
DE19860542A1 (en) * 1998-12-23 2000-06-29 Knoell Hans Forschung Ev An enzyme fragment with hyaluronate lyase activity is derived from streptococci and used for medical applications
WO2000038732A1 (en) * 1998-12-23 2000-07-06 Esparma Gmbh Hyaluronate lyase used for promoting penetration in topical agents
EP1228767A1 (en) * 2001-01-31 2002-08-07 S.A.R.M. S.r.l. Use of beta-Glucuronidase for the treatment of immune or allergic diseases
US6689349B1 (en) 1998-12-23 2004-02-10 Esparma Gmbh Skin protection agents containing a fragment mixture produced from hyaluronic acid by hydrolysis
RU2519634C1 (en) * 2013-04-17 2014-06-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Астраханская государственная медицинская академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО АГМА Минздрава России) Method for complex rehabilitation of children with chronic microbial-inflammatory urinary involvement with low immune status

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0106812A2 (en) * 1982-10-08 1984-04-25 Istituto Farmacologico Serono Pharmaceutical composition containing a fibrinolytic agent and a diffusion factor, useful for the treatment of the myocardium infarction
EP0106812A3 (en) * 1982-10-08 1985-09-11 Istituto Farmacologico Serono Pharmaceutical composition containing a fibrinolytic agent and a diffusion factor, useful for the treatment of the myocardium infarction
DE19860542A1 (en) * 1998-12-23 2000-06-29 Knoell Hans Forschung Ev An enzyme fragment with hyaluronate lyase activity is derived from streptococci and used for medical applications
WO2000038732A1 (en) * 1998-12-23 2000-07-06 Esparma Gmbh Hyaluronate lyase used for promoting penetration in topical agents
US6689349B1 (en) 1998-12-23 2004-02-10 Esparma Gmbh Skin protection agents containing a fragment mixture produced from hyaluronic acid by hydrolysis
US6719986B1 (en) 1998-12-23 2004-04-13 Esparma Gmbh Hyaluronate lyase used for promoting penetration in topical agents
EP1228767A1 (en) * 2001-01-31 2002-08-07 S.A.R.M. S.r.l. Use of beta-Glucuronidase for the treatment of immune or allergic diseases
RU2519634C1 (en) * 2013-04-17 2014-06-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Астраханская государственная медицинская академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО АГМА Минздрава России) Method for complex rehabilitation of children with chronic microbial-inflammatory urinary involvement with low immune status

Also Published As

Publication number Publication date
DE1767038A1 (en) 1971-09-09
FR8032M (en) 1970-08-03

Similar Documents

Publication Publication Date Title
ATE77556T1 (en) STABILIZED HUMAN PROTEIN PREPARATIONS.
ATE131042T1 (en) PHARMACOLOGICAL PREPARATION CONTAINING POLYELECTROLYTE COMPLEXES IN MICROPARTICULAR FORM AND AT LEAST ONE ACTIVE INGREDIENT.
TR199701071T2 (en) Compounds and compositions for delivery of the active substance.
DE69401204D1 (en) GONADOTROPINE CONTAINING FREEZER DRIED DROPS
KR860005636A (en) Injection composition containing Spergualin as an active ingredient and its preparation method.
GB1253831A (en) 9alpha,21-DIHALOPREGNANE COMPOUNDS
FI961169A0 (en) Crystalline anhydrous mycophenolate mofetil and intravenous formulation thereof
DE68927379D1 (en) SLIDE BLOCKING PEPTIDES
GB1179787A (en) Stabilised and Potentiated Therapeutic Enzyme Compositions
GB1281719A (en) Anti-haemorrhoidally active preparations for local or rectal administration
GB1136039A (en) Improvements relating to immunosuppressive agents
IE35507L (en) Preparations containing tetrahydrocarbazole¹derivatives
Onosaka et al. Roles of metallothionein in the liver on acute cadmium toxicity in mice. I. Effects of cycloheximide.
GB1269898A (en) Amino acid derivatives
GB1159174A (en) Pharmaceutical Compositions
GB1463908A (en) 1-dimethylamino-methyl-6-substituted-4h-s-triazolo-4,3-a- 1,4-benzodiazepine
GB1225584A (en)
GB1227238A (en)
GB1214663A (en) Benzodiazepine derivatives
GB1300277A (en) Therapeutic insulin compositions
ITRM920760A0 (en) AMINOACYLIC AND OLIGOPEPTIDE DERIVATIVES OF B-SUBSTITUTED HYPOXANTHIN WITH IMMUNOSTIMULANT ACTIVITY AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
GB1185235A (en) Anti-Malignant Tumor Composition
GB1305488A (en)
GB1185616A (en) 2-Sulfanilamido-3-Halogeno-Pyridines
JPS5758630A (en) Interferon inducer